Biohealth Innovation
Every year, millions of fish raised in aquaculture die of nervous necrosis virus (NNV). “The disease affects the brain, and the fish lose their vision and balance,” says Vikram Vakharia, professor of marine biotechnology at UMBC. As a result of damage to the nervous system, “the fish just swim in circles,” Vakharia says. His lab is housed at the Institute of Marine and Environmental Technology (IMET) on Baltimore’s Inner Harbor.
Leiden-based biotechnology company Mimetas has received 1.6 million USD funding for development of an organ-on-a-chip model for neurotoxicity. The aim of the project is to improve existing neurotoxicity tests and to reduce experimentation on animals. A panel of experts from BASF, Sanofi, GlaxoSmithKline, Abbvie, NC3Rs and renowned academic institutions has selected the Mimetas solution from a lineup of strong competitors. Mimetas will lead the consortium, which also includes the Institute for Risk Assessment Sciences (Utrecht, The Netherlands) and Cellular Dynamics International (Wisconsin, USA).
Rockville, MD, November 19, 2014 – BeneVir BioPharm, Inc. today announced it closed a Series A investment round with Pansend, LLC, an indirect wholly owned subsidiary of HC2 Holdings, Inc. (OTCQB: HCHC). BeneVir’s core technology was licensed from New York University (NYU) and originally developed by Ian J. Mohr, Ph.D., NYU Langone Medical Center.
BeneVir used this core technology to develop a pipeline of cancer immunotherapy drug candidates that affect antigen presentation in both tumor cells and antigen presenting cells. BeneVir’s pipeline consists of oncolytic viruses delivered locally or systemically. Once inside tumors, the viruses selectively destroy cancer cells, evade elimination by the immune system, and activate multiple classes of anti-tumor immune cells. This multi-mechanistic approach builds upon key elements of both oncolytic virus and immune-checkpoint inhibitor approaches to cancer treatment and is designed to block the major methods that tumors use to subvert the immune system. Proceeds of the financing will be used to conduct initial proof- of-concept clinical studies of BeneVir’s lead product, further develop the pipeline, and establish partnerships to test promising combination therapies in a diverse set of metastatic solid tumors.
Benevir has been accepted into the Hive program and will be taking part in the TEDMED 2014 convention from September 10-12, 2014 in Washington, DC and San Francisco.
BeneVir's cancer therapeutic is designed to induce the immune system to recognize and rid the body of two types of tumor cell. The first type is responsive to current immunotherapies, and many patients experience complete remissions. Tumor cells of the second type have evolved to hide from the immune system and are refractory to current immunotherapies. These tumor cells are ultimately responsible for tumor recurrence and poor clinical outcomes. To our knowledge, there is no technology in development that can induce immunity to both types of tumor cell. We feel we have a unique perspective in the emerging field of cancer immunotherapy and that our technology will exhibit enhanced clinical benefit for a wide range of cancer patients.
Read the full interview after the jump!
We are pleased to announce that emocha Mobile Health launched its video-based directly observed therapy application, miDOT, in Harris County, Texas. miDOT will be used to bridge the distance between healthcare workers and the tuberculosis (TB) patients that are dispersed across the nearly 1,800 square miles surrounding Houston, which has one of the nation’s highest Tuberculosis rates. The roll-out began in early February after emocha won a competitive bidding process based on a head-to-head pilot with competing technologies.
July 8 - 9, 2015, Boston, MA, USA
The first ever Organ-on-a-Chip World Congress focuses on Organ-on-a-Chip technology, Biofabrication and 3D-Bioprinting in the life sciences. The conference will be held on 8-9 July 2015 in Boston, organized by Selectbio.
MIMETAS is corporate sponsor of this inaugural conference.
Oral Presentation Abstract Submission Deadline: February 27, 2015
Poster Submission Deadline: June 30, 2015
Maarssen, the Netherlands, 14 June 2013 - MIMETAS was awarded the prestigious LifeSciences@Work award during yesterdays' Dutch Life Sciences SME Event. 75 recently established Life Science companies were invited to compete through an on-line video pitch contest. The video pitches were analyzed by a professional jury, consisting of primarily investors and life science professionals.
MIMETAS today announces the appointment of Herbert L. Heyneker, Ph.D. as Chairman of the Board of Directors. Dr. Heyneker will be supporting MIMETAS in her mission to develop high-throughput Organ-on-a-Chip products for predictive therapy testing.
"Organ-on-a-Chip technology is extremely hot in the United States today. But none of the technologies I've seen so far comes even close to the level of elegance and sophistication that MIMETAS is offering." says Herb Heyneker, who is based in the San Francisco Bay area. "I am strongly convinced that MIMETAS technology has the potential to create a revolution in medicine development and therapy selection. [...]"
MIMETAS' co-founder Paul Vulto has won the Audience Award and the runner up Jury Award for Best Proposition at the International Conference on the Commercialisation of Micro- and Nanosystems (COMS). The jury, which included serial entrepreneur Steven Walsh and Silicon Valley entrepreneur Janusz Bryzek, called the MIMETAS proposition a technology that will change the world, having the potential to grow into a billion-dollar company.
The UK-based National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) has awarded MIMETAS with £100k in the NephroTube Crack-it Challenge, sponsored by GlaxoSmithKline, Pfizer and Roche.
The NephroTube Crack-it Challenge aims to develop a microfluidic renal model predicting renal toxicity during pre-clinical development. In collaboration with the UMCN Pharmacology-Toxicology Department and the Swiss FHNW, MIMETAS will develop a kidney-on-a-chip by combining its OrganoPlate™ 3D-culturing technology with the human renal cell line ciPTEC™.
MIMETAS and BHI created a U.S. subsidiary of MIMETAS to access the clinical, regulatory and scientific resources available in Central Maryland and to access the U.S. marketplace, the largest life sciences market in the world.
"We're very pleased to add Todd to the MIMETAS team," said Jos Joore, Ph.D., Chief Business Officer of MIMETAS. "Todd couples a vast experience in business creation with a profound understanding of biology and disease mechanisms. Most importantly, Todd shares our sense of urgency around enabling better medical treatment by using more predictive cell culture models."
MIMETAS and Galapagos will collaborate to develop miniaturized 3D cell culture models that mimic specific aspects of human diseases. These models will be applied to the identification and improvement of novel compounds. Dr. Richard Janssen, Senior Director of Target Discovery at Galapagos, states: "The MIMETAS platform is the first to combine organ-on-a-chip technology with our high throughput screening of primary human cells. As we see it, OrganoPlates™ make 3D culture as straightforward as traditional cell culture."
MIMETAS is part of Medical Delta: the consortium of top life sciences and medical technology partners in the Netherlands. Medical Delta is a research, sales and logistics driven life sciences and medical technology cluster situated in the economic heart of the Netherlands, between Amsterdam Schiphol Airport and the Port of Rotterdam. In this Leiden -- Delft -- Rotterdam region, top-ranked universities and medical centers work together with industry and government to provide a dynamic environment for innovative spinoffs and international companies. With thanks to Roel Kamerling.
What do you need to turn a brilliant idea into a business? “A good morale boost,” says Abhishek Motayed, Founder and President of N5 Sensors, Inc. of Rockville. Motayed had that boost this month when N5 Sensors received two Small Business Innovation Research (SBIR) awards totaling $250,000. The grants came from the Environmental Protection Agency (EPA) and the National Science Foundation (NSF) towards N5 Sensors work developing low-power, computer chip-size benzene, carbon monoxide, and ammonia sensors. A 2012 UMD Invention of Year Award winner, Motayed has kept close contact with the university’s Office of Technology Commercialization (OTC), a crucial participant in the creation of N5 Sensors. “My interactions with OTC were very positive and encouraging. They are very knowledgeable—they knew exactly how to advise me on funding, commercialization, and patenting,” says Motayed.
Strand Life Sciences (Strand) representatives will demonstrate new capabilities of the company's variant interpretation and reporting software, StrandOmics at the Association For Molecular Pathologist (AMP) 2014 Annual Meeting to be held from November 12th to 15th in National Harbor, Maryland. The 20th anniversary meeting's theme is "Realizing the Dream of Precision Medicine," with a special address by Dr. Francis Collins, Director of the National Institute of Health. At AMP, Strand will host a workshop on the innovative developments and application of its StrandOmics software, plus new expansion efforts in Personalized Medicine.
Apollo Hospitals announced the launch of cutting-edge clinical genomic tests from the Strand Center for Genomics and Personalized Medicine, a part of Strand Life Sciences across its hospital network. These tests in oncology, cardiovascular, heritable eye diseases and rare genetic disorders shall be integrated into clinical practice by Apollo’s subsidiary, Sapien Biosciences in partnership with Strand Life Sciences. These tests, will help doctors diagnose disease more precisely, identify the optimal treatment and monitor disease & treatment course for better outcomes. Genomics is integral to Apollo’s focus on Research and Innovations. Genomic testing involves analyses of patient genomes – genes and sequences of DNA/RNA. The analysis helps create better prognostic tools for improved disease screening and prevention strategies. The patient benefits from optimized clinical care, personalization of treatment & monitoring of outcomes. These tests come with comprehensive pre- & post-test counselling to help the patient & their physicians to integrate the tests results into the clinical care provided. Ms. Sangita Reddy, Joint Managing Director, Apollo Hospitals says,“Apollo has always believed that personalized medicine is the future of healthcare delivery. Our Chairman, Dr. P.C Reddy’s foresight of personalized health is becoming a reality today with the availability of such cutting-edge genomic tests.”
In this episode of BioTalk, host Rich Bendis is joined by Amitabh Varshney, Dean of the College of Computer, Mathematical, and Natural Sciences and a Professor of Computer Science at the University of Maryland, College Park. Together, they explore the groundbreaking advancements in artificial intelligence and health computing driven by the University of Maryland (UMD).
Dean Varshney discusses the launch of the Artificial Intelligence Interdisciplinary Institute at Maryland (AIM) earlier this year. He shares insights into the vision behind AIM, the strategic hiring of new faculty, the allocation of seed grants, and the development of academic programs in AI, all solidifying UMD's position as a leader in this rapidly evolving field.
Listen Now via your favorite podcast platforms:
Apple: https://apple.co/40OFPe9
Spotify: https://spoti.fi/4aGnW4A
Amazon Music: https://amzn.to/4jM9e07
YouTube Music: https://bit.ly/4hnw8Je
TuneIn: https://bit.ly/4hbf2hV
In this episode of BioTalk with Rich Bendis, Dr. Kolaleh Eskandanian, Vice President and Chief Innovation Officer at Children’s National Hospital, discusses her work driving pediatric healthcare innovation. Dr. Eskandanian introduces the BARDA SPARK Accelerator, a groundbreaking initiative focused on advancing medical countermeasures for children, and explains how it aligns with Children’s National’s mission to lead in pediatric healthcare innovation.
She also highlights the unique challenges in developing pediatric medical countermeasures and the importance of partnerships with organizations like Rainbow Babies, Mass General, and others. Additionally, Dr. Eskandanian shares insights into the hospital’s role in fostering innovation through the National Capital Consortium for Pediatric Device Innovation (NCC-PDI) and the Children’s National Research and Innovation Campus.
Join us for an engaging conversation about the future of pediatric healthcare, the opportunities for innovation, and how the SPARK Accelerator is paving the way for advancements that will improve the lives of children worldwide.
Listen now via your favorite podcast platforms:
Apple: https://apple.co/4gcz9L3
Spotify:https://apple.co/4gcz9L3
Amazon Music: https://apple.co/4gcz9L3
YouTube Music: https://bit.ly/4hp4WK0
TuneIn: https://bit.ly/42oIoVk
In this episode of BioTalk, Bill Tompkins, President and CEO of the Montgomery County Economic Development Corporation (MCEDC), discusses the strategies driving Montgomery County’s position as a leading bioscience hub. Bill highlights MCEDC’s role in reinforcing the region’s standing as the third-largest bioscience cluster in the U.S. and shares insights into the new Institute for Health Computing. He also introduces two new venture funds—the Technology Innovation Fund and the Founders Fund—designed to accelerate innovation and support local entrepreneurs.
Bill outlines MCEDC’s priorities for the upcoming year, emphasizing economic growth, investment opportunities, and fostering collaborations that make Montgomery County a thriving ecosystem for business and life sciences.
Listen now via your favorite podcast platforms:
Apple: https://apple.co/4j6AA0e
Spotify: https://spoti.fi/4iXajSl
Amazon Music: https://amzn.to/3W3Tb3i
YouTube Music: https://bit.ly/3W9hixH
TuneIn: https://bit.ly/427OmtP
In this episode of BioTalk, host Rich Bendis welcomes Ric Hughen, CEO of Linshom Medical, and Talia Feldman, Software Engineer at Linshom Medical, to discuss their groundbreaking advancements in respiratory monitoring technology. As the main winners of the 2024 Crab Trap Competition at the 10th Annual BioHealth Capital Region Week, Ric and Talia share Linshom’s mission to improve patient safety through their innovative and accessible respiratory monitoring devices.
Ric explains how Linshom is addressing critical gaps in respiratory monitoring by bringing operating-room-quality data to patient bedsides and homes. Talia shares insights from the engineering side, highlighting the challenges and breakthroughs in developing reliable and user-friendly technology.
Listen now via your favorite podcast platform:
Apple: https://apple.co/4eVTWSO
Spotify: https://spoti.fi/4geg0c2
Amazon Music: https://amzn.to/4g5bIUy
TuneIn: https://bit.ly/4f5e3hu
YouTube Music: https://bit.ly/41deVxa
The conversation explores Linshom’s roots in the BioHealth Capital Region and how its partnerships and resources have been instrumental to the company’s growth. Talia reflects on her experience presenting at the Crab Trap Competition, and Ric discusses how this recognition aligns with Linshom’s broader visibility and growth objectives.
In this episode of BioTalk with Rich Bendis, Dr. Eric Edwards, Co-Founder and CEO of MedPhlow, shares how his innovative company is reshaping emergency medicine through cutting-edge drug delivery systems. Dr. Edwards discusses his journey from co-founding Kaléo, where he helped develop life-saving products like AUVI-Q, to leading MedPhlow, a subsidiary of Phlow Corp. Based in Richmond, VA, MedPhlow is dedicated to addressing critical challenges in essential medicine delivery, with its first product focused on improving outcomes during sudden cardiac arrest.
Dr. Edwards explains the groundbreaking technology behind MedPhlow’s platform and how it is poised to transform emergency care. He also highlights the impact of investor partnerships, such as those with Virginia Venture Partners, and discusses MedPhlow’s next milestones in its mission to make emergency medicine more efficient and accessible.
As a part of the BioHealth Capital Region, Dr. Edwards reflects on the advantages of being based in this vibrant hub of innovation and his contributions as a BioHealth Innovation (BHI) board member. Tune in to learn about the future of MedPhlow and the inspiring work being done to advance life-saving solutions in healthcare.
Listen via your favorite podcasting platform:
Apple: https://apple.co/3Z7GqWf
Spotify: https://spoti.fi/3YYh6Sq
Amazon Music: https://amzn.to/4i16tXI
TuneIn: https://bit.ly/4hWAiJ7
Join us for an insightful episode of BioTalk as Rich Bendis speaks with Eric Mayton, CEO of Cerillo, one of the recent winners at the Crab Trap competition during the 10th Annual BioHealth Capital Region Week. Cerillo, based in Charlottesville, VA, is making waves in microbiome research and biological product development with its innovative tools designed to tackle variability challenges and enhance data collection efficiency.
In this episode, Eric shares Cerillo’s mission to combat Eroom's Law—the increasing cost and time in drug development—through affordable and accessible research tools like the Stratus and Alto microplate readers. We also dive into the impact of Cerillo’s co-culture duet system, which is transforming cellular interaction studies in fields such as antimicrobial resistance and biofuel development.
Listen via your favorite podcast platform:
Apple - https://apple.co/3Cw22DT
Spotify - https://spoti.fi/40QSuxu
Amazon Music - https://amzn.to/40MEIvU
Tunein - https://bit.ly/4eyK01b
In this episode of BioTalk, Rich Bendis sits down with Rachel Rath, the Head of JLABS @ Washington, DC, to discuss her journey and insights on building a thriving ecosystem for life sciences innovation. Rachel shares her academic and professional background, from roles at PCORI and BARDA Blue Knight to leading JLABS @ Washington, DC. She offers an in-depth look at JLABS’ national and international footprint, and the significant partnerships with organizations like Children’s National, Virginia Tech, and BARDA that strengthen the innovation landscape across the mid-Atlantic.
Tune in as Rachel shares the current priorities at JLABS, highlighting the diversity of its tenant portfolio, which spans MedTech, Pharma, and Integrated Healthcare Solutions. She also discusses how JLABS companies benefit from the support and resources available through Johnson & Johnson, including access to valuable connections, mentorship, and funding opportunities via JJDC.
Listen now via your favorite podcasting platform:
Apple: https://apple.co/4fybjcO
Spotify: https://spoti.fi/4eenlXO
Amazin Music: https://amzn.to/3NRxK0P
TuneIn: https://bit.ly/4ecryv7
In this episode of BioTalk, Rich Bendis speaks with Dr. Frank Gupton, Co-Founder of Phlow and CEO of the Medicines for All Institute, about his pioneering efforts to improve pharmaceutical manufacturing and global access to essential medications.
Dr. Gupton shares how Phlow is addressing vulnerabilities in the U.S. pharmaceutical supply chain by producing critical medicines domestically, and how the Medicines for All Institute is reshaping the way drugs are made by reducing costs and streamlining production. Drawing on his extensive experience in the pharmaceutical industry, Dr. Gupton discusses the ongoing challenges of ensuring that lifesaving medicines reach those in need worldwide.
Listen now on your favorite podcast platform:
Apple: https://apple.co/40fndE6
Spotify: https://spoti.fi/3BUBe00
Amazon Music: https://amzn.to/4hbHYqm
TuneIn: https://bit.ly/2M60Wmx
The discussion also touches on the future of pharmaceutical manufacturing, from emerging technologies like continuous processing to green chemistry's role in creating more sustainable production methods. Dr. Gupton provides insight into how partnerships and collaboration are vital to accelerating these innovations.
Join the conversation to hear about the impactful work being done to transform drug manufacturing and access on a global scale.
In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., sits down with Peter Ronco, Chief Executive Officer of Emmes, a global full-service Clinical Research Organization (CRO). Peter discusses his transition from leading roles at Janssen R&D and Bristol Myers Squibb to guiding Emmes' strategic direction and operations.
Peter introduces Emmes, its growth as a full-service CRO, and the recent partnership with New Mountain Capital that has accelerated global acquisitions and diversified services. He also discusses the formation of the Emmes Group, which includes Veridix AI, and the latest partnership with Mimansa AI, highlighting the impact of AI in clinical research.
Listen now via your favorite podcasting platforms:
Apple:https://apple.co/2QwoEIl
Spotify: https://spoti.fi/4dJCNf6
Amazon Music: https://amzn.to/3Zfhzl7
TuneIn: https://bit.ly/3Xbi3Gf
The conversation also covers the strategic importance of Rockville, Maryland, as Emmes' headquarters and why Montgomery County is an ideal location. Peter wraps up by outlining Emmes' future growth plans.
In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., welcomes Brad Sibbald, Vice President of Kelly Science and Clinical, and Sarah Porter, Vice President of Government Solutions at Kelly Services. Together, they explore the critical trends and strategies shaping the biotech and government workforce landscapes, with a particular focus on the BioHealth Capital Region (BHCR).
Kelly Services, a global leader in workforce solutions, plays a pivotal role in connecting talent with opportunities across various industries, including science, engineering, technology, and telecommunications. Brad and Sarah provide valuable insights into how Kelly Services is adapting to the evolving needs of the biotech sector, from commercial enterprises to government agencies.
Listen now via your favorite podcasting platform:
Apple: https://apple.co/4dSL8N6
Spotify: https://spoti.fi/4e1sl2t
Amazon Music: https://amzn.to/3zLNbUw
TuneIn: https://bit.ly/2M60Wmx
The discussion covers various topics, including the current talent landscape in the BHCR, strategies for maintaining a robust pipeline, and the challenges of retaining top talent in an increasingly competitive market.
Additionally, we learn about Kelly’s upcoming virtual job fair in September (https://bit.ly/3yMuiRm), an event for those looking to connect with opportunities in the biotech sector and the 2024 Kelly Global Re:work Report (https://bit.ly/3SSVhBl), offering listeners valuable insights into the future of work and workforce trends globally.
In this special episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., hosts a compelling discussion with three groundbreaking guests from South Africa: Johann de Bruyn, CEO of TASK, Ethan Hunter, Chief Operations Officer at Immobazyme, and Dr. Carla Eksteen, Postdoctoral Research Fellow at Stellenbosch University. Together, they share their journey of connecting South Africa's biotech scene with the BioHealth Capital Region, showcasing how innovation transcends borders.
Johann de Bruyn opens the conversation by introducing TASK Applied Science and its collaborative relationship with the U.S. He explains the genesis of Bio Centrifuge Africa, a business plan competition inspired by the BioHealth Capital Region's Crab Trap, designed to bridge the gap between South Africa’s emerging biotech sector and the established BHCR.
Ethan Hunter, co-founder of Immobazyme, discusses his company’s pioneering work in precision fermentation and the growing impact it has across various industries. He reflects on the significance of winning Bio Centrifuge Africa and the exciting opportunity to compete in the 9th Annual Crab Trap in Maryland this September.
Dr. Carla Eksteen shares her research journey in cancer immunotherapy and the vital role her work plays in advancing healthcare in South Africa. She talks about the opportunities provided by Bio Centrifuge Africa and her upcoming trip to Maryland as part of the competition winners.
Listen now on your favorite podcast platform:
Apple: https://apple.co/3SUCMwz
Spotify: https://spoti.fi/3XbF9wv
Amazon Music: https://amzn.to/3Mbzph1
TuneIn: https://bit.ly/3MbzqBB
In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., welcomes guests from ARPA-H: Craig Gravitz, Director of the Project Accelerator Transition Innovation Office (PATIO), and Jenica Patterson, Ph.D., Portfolio Lead at ARPA-H. Together, they provide a comprehensive overview of ARPA-H's mission and innovative programs.
Craig Gravitz and Jenica Patterson share their educational and career backgrounds, setting the stage for a discussion about ARPA-H and its various initiatives. They provide insights into how ARPA-H differentiates itself from other agencies like HHS and NIH, while also highlighting their collaborative efforts.
Listen now via your favorite podcast platform:
Apple: https://apple.co/4dy5wmS
Spotify: https://spoti.fi/3yDIV9k
Amazon Music: https://amzn.to/3AcL3FI
TuneIn: https://bit.ly/3LV54Dg
Listeners will learn about the Project Accelerator Transition Innovation Office (PATIO) and its crucial role within ARPA-H. Jenica Patterson discusses her portfolio, including key areas and projects, and provides details on the new women's sprint for health initiative and its funding tracks.
In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., speaks with Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News. Alex joins the podcast to discuss the latest Top 10 U.S. Biopharma Clusters list, where the BioHealth Capital Region secured its #3 ranking for the second consecutive year.
The conversation highlights the factors that contributed to the success of the top biopharma clusters, focusing on early investments in biotech, the generation of high-quality science, building networks with partners, and broadening clusters beyond anchor businesses. Alex elaborates on how these regions have sustained their scientific excellence and the long-lasting impact of pioneering efforts.
Listening now on your favorite podcast platforms:
Apple: https://apple.co/4bYl81G
Spotify: https://spoti.fi/3zVLIuU
Amazon Music: https://amzn.to/4d6dBiQ
TuneIn:https://bit.ly/4fBDs3R
In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., speaks with Matt Gardner, Head of Life Sciences, Americas, at CBRE. With over 30 years of experience in the technology and life sciences sectors, Matt Gardner provides a comprehensive look at the latest trends and developments in the life sciences industry.
Matt shares key findings from CBRE's recently released U.S. Life Sciences Talent Trends' report for 2024, offering insights into what the life sciences sector can expect in the coming year. He discusses the national real estate market, highlighting the differences between office space and life science wet lab space, and emerging trends in the sector.
The conversation explores the strategic importance of the BioHealth Capital Region (BHCR), consistently ranked as a top market for life sciences research talent. Matt elaborates on what makes this region crucial for CBRE and the life sciences sector as a whole.
Listen now via your favorite podcast platform:
Apple: https://apple.co/4bSOnmo
Spotify: https://spoti.fi/4bVsX8r
Amazon Music: https://amzn.to/3zLNbUw
TuneIn: https://bit.ly/2M60Wmx
In this episode of BioTalk with Rich Bendis, we have the honor of speaking with the U.S. Ambassador to the Republic of Tunisia, Joey R. Hood. With an impressive diplomacy and international relations background, Ambassador Hood sheds light on the vital collaboration between the U.S. and Tunisia in scientific research, innovation, and technology transfer.
Ambassador Hood discusses the current status of U.S.-Tunisia cooperation in scientific research and technology transfer, emphasizing these areas’ critical role in Tunisia’s development. He highlights the importance of scientific research, innovation, and technology transfer in Tunisia and explains how the U.S. can support and enhance these efforts.
Click here to listen via your favorite Podcast platform:
Apple: https://apple.co/4cX1YKr
Spotify: https://spoti.fi/4cG6xJt
Amazon Music: https://amzn.to/3WneYDC
TuneIn: https://bit.ly/2M60Wmx
Join us for an episode of BioTalk with Rich Bendis featuring Dr. Bradley Maron, Senior Associate Dean for Precision Medicine and Executive Co-Director of the University of Maryland-Institute for Health Computing at the University of Maryland School of Medicine. With his extensive background in cardiovascular research and precision medicine, Dr. Maron offers a wealth of knowledge and innovative perspectives.
In this episode, Dr. Maron shares his professional journey, discussing his various roles at the University of Maryland and what drew him to the region. He provides a comparative analysis of the ecosystems in Boston/Harvard and Maryland/University of Maryland, highlighting the unique attributes and opportunities within each.
Dr. Maron introduces the Institute for Health Computing (IHC), explaining its creation, mission, and strategic partnerships with the University System of Maryland and Montgomery County. He outlines the significance of data science in improving health and wellness, addressing its increasing role and challenges.
Listen Now Via Your Favorite Podcast Platforms:
Apple:https://apple.co/3VMHpt9
Spotify: https://spoti.fi/3VEOTOI
Amazon Music: https://amzn.to/4eIj14H
TuneIn:https://bit.ly/4eJvgxU
Join us for a compelling episode of BioTalk with Rich Bendis as we welcome Dr. Michelle E. Tarver, Deputy Center Director and Chief Transformation Officer at the Center for Devices and Radiological Health (CDRH) at the US Food and Drug Administration (FDA). With a distinguished background as a board-certified ophthalmologist and epidemiologist, Dr. Tarver is at the forefront of transforming the evaluation and inclusion of medical devices in underserved and underrepresented populations.
In this episode, Dr. Tarver introduces the FDA and the CDRH Division, explaining the definition of a medical device by FDA standards. She discusses the creation of the Chief Transformation Officer role within the FDA, highlighting its importance and the strategic vision behind it.
Listen now via your favorite podcast platforms.
Apple: https://apple.co/3VFF5UK
Spotify: https://spoti.fi/3RC9sug
Amazon Music: https://amzn.to/4cdYqn8
TuneIn: https://bit.ly/4czGVO0
We explore the critical importance of diversity, equity, and inclusion (DEI) in evaluating medical devices, and how these efforts are essential for ensuring equitable healthcare for all. Dr. Tarver introduces the innovative “Home as a Health Care Hub” initiative by the FDA/CDRH, explaining its potential to revolutionize healthcare delivery.
Join us for an enlightening episode of BioTalk with Rich Bendis as we welcome Dan Berglund, President and CEO of SSTI. With nearly four decades of experience in tech-based economic development (TBED), Dan has been a pivotal figure in shaping the landscape of innovation and entrepreneurship across the nation.
In this episode, Dan shares the history and evolution of Technology Based Economic Development, discussing key initiatives in states like Ohio and Pennsylvania, and at the federal level. He highlights the importance of partnerships, detailing a compendium of state and federal cooperative technology programs that have driven progress in the field.
We explore the early years of SSTI, looking into its creation, mission, and initial goals, and how it has grown to support a nationwide network dedicated to fostering tech-based economies. Dan discusses the evolution and growth of state TBED programs, and the changing role of the federal government in supporting these initiatives through agencies like STCS, OSTP, Commerce, NIST, and EDA.
Listen now via:
Apple: https://apple.co/3RwdqEJ
Spotify: https://spoti.fi/3RrmIlh
Amazon Music: https://amzn.to/3vpZDHI
TuneIn: https://amzn.to/3xvGFjX
Dan also emphasizes the importance of private/public TBED partnerships, sharing insights into how these collaborations have bolstered economic growth and innovation. As he prepares to step down from his role after 28 years,and assume a part time role, Dan discusses the recruitment of a new CEO and reflects on SSTI's achievements, his legacy, and his vision for the organization's future.
Additionally, Dan talks about Rich Bendis’s role as an original founding board member of SSTI, and his significant help in the early development of the organization. He also highlights the presence of several SSTI members in the BioHealth Capital Region.
Join us for an enlightening episode of BioTalk with Rich Bendis, featuring Michael J. Tarlov, Chief of the Biomolecular Measurement Division at the Material Measurement Laboratory, NIST. With a distinguished career in analytical chemistry and extensive experience in biochemical sensing and bioprocess measurements, Michael leads critical initiatives to advance biotechnology and healthcare.
In this episode, we delve into the pivotal role of NIST as a non-regulatory agency within the Department of Commerce, highlighting its profound impact on measurement science, gene therapy, gene editing, synthetic biology, and regenerative medicine. Michael shares insights into NIST's collaborations, including local companies like MedImmune/AstraZeneca and Novavax, and the importance of partnerships with academic institutions like the University of Maryland in driving local biotech advancements.
Listen now via: